Drug repurposing: a better approach for infectious disease drug discovery?
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The advent of publically available databases containing system-wide phenotypic data of the host response to both drugs and pathogens, in conjunction with bioinformatics and computational methods now allows for in silico predictions of FDA-approved drugs as treatments against infection diseases. This systems biology approach captures the complexity of both the pathogen and drug host response in the form of expression patterns or molecular interaction networks without having to understand the underlying mechanisms of action. These drug repurposing techniques have been successful in identifying new drug candidates for several types of cancers and were recently use to identify potential therapeutics against influenza, the newly discovered Middle Eastern Respiratory Syndrome coronavirus and several parasitic diseases. These new approaches have the potential to significantly reduce both the time and cost for infectious diseases drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418 · cited 1×
“This was done by constructing individual disease-specific networks using a global human protein – protein interaction network and gene expression datasets for each disease [19].”
MethodNetwork biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903 · cited 1×
“Biomole-cular networks connect molecular components, such as genes, proteins, or metabolites by specific types of interactions and are used to represent the functional relationship among the various components of the network [12].”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · cited 1×
“…an in-depth review of network-based approaches for drug repurposing is beyond the scope of this article, several recent reviews have focused on the complexity of human disease networks [16], tools for analyzing network topology and dynamics [4 (cid:2) ], and network and drug combinations [17].”
BackgroundHindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., & Manolio, T. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903103106 · Cited by 4,013
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · cited 2×
“[7,9] was used to compare a compendium of 164 known drug compounds in cMap to an IBD-specific gene expression signature derived from 176 datasets available in Gene Expression Omni-bus (GEO).”
Method
Cited by
Das, S., Sarmah, S., Lyndem, S., & Singha Roy, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1763201 · Cited by 380
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
“Over the last decade, the antiviral properties of repurposed drugs have gained considerable attention due to the lack of targeted treatments for specific emerging viruses (Law et al., 2013).”
Drug repurposing to fight colistin and carbapenem-resistant bacteria
Peyclit, L., Baron, S. A., & Rolain, J.-M. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00193 · Cited by 91
Kim, J. H., Cheng, L. W., Chan, K. L., Tam, C. C., Mahoney, N., Friedman, M., Shilman, M. M., & Land, K. M. (2020) · Antibiotics · doi:10.3390/antibiotics9110812 · Cited by 71
“In silico/computational repurposing approaches typically use four steps: (1) mining and compilation of pathogen genome data, (2) homology modeling, (3) ligand preparation and molecular docking, and (4) experimental validation in the target pathogens [173].”
MethodNew role for FDA-approved drugs in combating antibiotic-resistant bacteria
Andersson, J. A., Fitts, E. C., Kirtley, M. L., Ponnusamy, D., Peniche, A. G., Dann, S. M., Motin, V. L., Chauhan, S., Rosenzweig, J. A., Sha, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00326-16 · Cited by 53
Metadata
- Authors
- Law, G. L., Tisoncik-Go, J., Korth, M. J., & Katze, M. G.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 25
- Issue
- 5
- Pages
- 588-592
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2005302698
- Cited by
- 90
- References
- 6
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.